Liquid biopsy for brain AVM mutations
Part of Brain & nervous system, Genetic & congenital, Heart & circulation clinical trials.
This study tests if a simple blood test can detect genetic changes in brain arteriovenous malformations (AVMs). If successful, it may help guide treatment without needing a tissue biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- Being treated for a brain AVM (cAVM)
- Your doctor has decided that embolisation (a procedure to block blood vessels) is right for you
- You are having a venous embolisation, with or without an arterial one
- You are willing to participate and have been informed about the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how brain arteriovenous malformations (abnormal connections between arteries and veins in the brain) behave over time, and how different treatment choices affect outcomes. It may help researchers better predict prognosis and guide future care.
This trial uses a blood test to look for genetic mutations in brain arteriovenous malformations (bAVMs). It may help doctors understand these lesions better and guide treatment.
This study looks at genetic (inherited DNA) factors in people with certain abnormal blood vessel connections in the brain or spinal cord. It may help researchers understand why these malformations happen and how they might behave over time.
This trial tests a medication called bevacizumab (given as an IV infusion) to see if it can improve symptoms in people with brain arteriovenous malformations (AVMs) that cannot be treated with standard therapies. It is for those whose AVMs cause significant disability.
This study checks people long-term after a procedure called embolization, which blocks abnormal blood vessel connections in the brain (arteriovenous malformations). It may help doctors learn how well the treatment lasts over time and what outcomes to expect.
This trial tests a liquid embolic agent (a gel-like material) injected into the blood vessels of a brain arteriovenous malformation (AVM) to block abnormal blood flow. It’s for people aged 18 to 80 with certain types of AVMs that doctors think can be treated this way.
Hear when a new Cerebral Arteriovenous Malformations trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.